The management of smoldering multiple myeloma (MM) is undergoing a significant transformation, driven by growing evidence that early intervention can meaningfully delay progression to active disease.

A potential first-ever FDA-approved treatment for smoldering myeloma received a positive review from an advisory committee, but not without reservations, even from panelists who voted in favor. By a 6 ...

SAN DIEGO -- The risk of progression from smoldering multiple myeloma to symptomatic disease decreased by 50% in patients treated with the anti-CD38 monoclonal antibody daratumumab (Darzalex), ...

Multiple myeloma is a type of blood cancer caused by a buildup of abnormal plasma cells in the bone marrow. As the abnormal plasma cells accumulate, they crowd out healthy cells and cause symptoms ...

Near the Saarland capital of Saarbrücken lies a unique natural phenomenon in Germany: the so-called Burning Mountain. The rock formation gets its name from an underground coal seam fire that has been ...